We are live on ! Find out more
PRME icon

Prime Medicine
PRME

105 hedge funds and large institutions have $433M invested in Prime Medicine in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 12

27% more funds holding

Funds holding: 83 → 105 (+22)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.64% less ownership

Funds ownership: 50.89% → 50.25% (-0.64%)

4% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 27

8% less capital invested

Capital invested by funds: $472M → $433M (-$39M)

33% less call options, than puts

Call options by funds: $375K | Put options by funds: $558K

Holders
105
Holders Change
+22
Holders Change %
+26.51%
% of All Funds
1.53%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
34
Increased
26
Reduced
27
Closed
12
Calls
$375K
Puts
$558K
Net Calls
-$183K
Net Calls Change
-$270K

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$3.97M
2
BlackRock
BlackRock
New York
+$3.42M
3
Morgan Stanley
Morgan Stanley
New York
+$2.93M
4
BG
Bollard Group
Massachusetts
+$2.78M
5
Two Sigma Investments
Two Sigma Investments
New York
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
-$12.8M
2
State Street
State Street
Massachusetts
-$7.14M
3
EC
EcoR1 Capital
California
-$5.72M
4
MCM
Moore Capital Management
New York
-$4.26M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$105M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$35.9M +$794K +103,118 +3%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$34.8M +$22.6K +2,930 +0.1%
BlackRock
4
BlackRock
New York
$33.5M +$3.42M +444,093 +13%
NAMA
5
Nikko Asset Management Americas
New York
$31.2M -$892K -115,819 -3%
Sumitomo Mitsui Trust Group
6
Sumitomo Mitsui Trust Group
Japan
$31.2M -$892K -115,819 -3%
AIM
7
ARK Investment Management
Florida
$27.8M +$3.97M +515,841 +20%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$19.7M +$368K +47,788 +2%
MM
9
MWG Management
British Virgin Islands
$15.9M – – –
RG
10
Redmile Group
California
$11.7M – – –
BBA
11
Baker Bros. Advisors
New York
$9.11M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$7.86M +$315K +40,866 +5%
DM
13
Deerfield Management
New York
$7.84M – – –
State Street
14
State Street
Massachusetts
$6.73M -$7.14M -926,243 -55%
GWM
15
Greenwich Wealth Management
Connecticut
$4.54M +$570K +73,980 +17%
Bank of America
16
Bank of America
North Carolina
$4.17M +$1.29M +167,954 +55%
SB
17
Samsara BioCapital
California
$4.17M – – –
Morgan Stanley
18
Morgan Stanley
New York
$3.75M +$2.93M +380,677 +890%
CC
19
Casdin Capital
New York
$3.25M – – –
BG
20
Bollard Group
Massachusetts
$3.2M +$2.78M +361,136 New
Northern Trust
21
Northern Trust
Illinois
$3.06M +$92.2K +11,969 +4%
Charles Schwab
22
Charles Schwab
California
$2.62M +$27.9K +3,618 +1%
Two Sigma Investments
23
Two Sigma Investments
New York
$2.38M +$1.35M +175,369 +189%
Ensign Peak Advisors
24
Ensign Peak Advisors
Utah
$1.33M – – –
Fidelity International
25
Fidelity International
Bermuda
$1.3M -$12.8M -1,658,616 -92%
1
2 3 4 5

PRME Hedge Fund Activity: Q4 2023 in Review

105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2023, worth a combined $433M — down 8.3% from $472M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new PRME positions and 12 closed out — a net gain of 22 holders — while 26 added to existing stakes and 27 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $3.97M. The largest seller was Fidelity International, cutting an estimated $12.8M.

  • 105 institutional investors held Prime Medicine (PRME) as of Q4 2023, up from 83 in Q3 2023.
  • Funds reported $433M of Prime Medicine stock for Q4 2023, down 8.3% quarter-over-quarter.
  • 34 funds opened new Prime Medicine positions in Q4 2023 and 12 closed out, a net change of +22 holders.
  • The largest Prime Medicine buyer in Q4 2023 was ARK Investment Management, an estimated $3.97M added.
  • The largest Prime Medicine seller in Q4 2023 was Fidelity International, an estimated $12.8M sold.

Based on aggregated 13F filings for Q4 2023.